A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2009 Planned end date changed from 1 Sep 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.